PPI Products Must Warn Of Possible Increased Fracture Risk - FDA
This article was originally published in The Tan Sheet
Executive Summary
FDA requires manufacturers to warn consumers that using proton pump inhibitors could increase the risk of some fractures, even though current research does not establish a causal link between the drug and fracture risk